Read the full article to learn more about these 4 recommendations for pharmaceutical and biotechnology manufacturers seeking to address inequities in access to healthcare:
- Use social determinants of health and electronic health records in forecasts of health outcomes.
- Help to address inequities in the social determinants of health.
- Ensure that clinical trial outcomes are representative of the entire population.
- Develop innovative collaborations with all stakeholders to determine value.
What does inequity in health mean?
When developing strategies for access to healthcare, the terms health inequality and inequity are sometimes confused or used interchangeably. They shouldn’t be, it’s important to recognize the difference between inequality and inequity:
- Inequality in health refers to the uneven distribution of health and/or resources due to factors such as genetics.
- Inequity in health refers to differences arising from social determinants such as governance or culture.
The 2 primary factors that contribute to inequities in health
The World Health Organization identifies two main clusters of root causes of health inequity.
The first is the intrapersonal, interpersonal, institutional, and systemic mechanisms that impact access to healthcare differentially across race, gender, class, sexual orientation, gender expression, and other determinants of individual and group identity.
The second is the unequal allocation of power and resources, including goods, services, and societal attention, which result in unequal social, economic, and environmental conditions. These are called the social determinants of health.